)
Overview
<ul>
<li>Medical technologies firm’s Q4 net sales rose 11.4%, beating analyst expectations</li>
<li>Adjusted EPS for Q4 increased 11.5%, beating analyst expectations</li>
<li>Company expects 2026 organic net sales growth of 8.0% to 9.5%</li>
</ul>
Outlook
<ul>
<li>Company expects 2026 organic net sales growth between 8.0% and 9.5%</li>
<li>Stryker forecasts 2026 adjusted EPS between $14.90 and $15.10</li>
<li>Company anticipates slightly positive impact from foreign exchange on 2026 results</li>
</ul>
Result Drivers
<ul>
<li>MEDSURG AND NEUROTECHNOLOGY GROWTH - Segment net sales increased 17.5% in Q4, driven by strong unit volume growth</li>
<li>ORTHOPAEDICS SEGMENT - Organic net sales increased 8.4% in Q4, driven by unit volume growth</li>
<li>OPERATING MARGIN IMPROVEMENT - Adjusted operating income margin increased 100 bps to 30.2% in Q4</li>
</ul>
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q4 net Beat $7.20 $7.12
sales bln bln (25
Analysts
)
Q4 Beat $4.47 $4.40
Adjusted (25
EPS Analysts
)
<h3>Q4 EPS $2.20</h3>
Analyst Coverage
<ul>
<li>The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 24 “strong buy” or “buy”, 8 “hold” and no “sell” or “strong sell”</li>
<li>The average consensus recommendation for the medical equipment, supplies &amp; distribution peer group is “buy”</li>
<li>Wall Street’s median 12-month price target for Stryker Corp is $432.50, about 20.9% above its January 28 closing price of $357.83</li>
<li>The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 25 three months ago</li>
</ul>
Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Stryker Q4 net sales rise 11.4%, beat estimates